Evommune (EVMN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Evommune (EVMN) is Moderate Underperform.

The composite score behind that read is -0.42, weighing +0.38 of bullish evidence against -0.44 bearish.

Evommune last closed at $6.61, -0.60% on the session.

Against the IVW growth benchmark the position is -1.21% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

17 graded predictions for EVMN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Evommune in the 16th percentile on return on equity, where 100 is best.

Evommune is classified under Health Care / Biotechnology, with a market capitalisation of $241.34M.

StockMap tracks Evommune as the 227th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Evommune ranks 334th of 365 in the group, against a group median of -0.21.